SCHEMBL5768465

SCHEMBL5768465

COc1ccc(N2Cc3cnc(Cl)nc3N(CC3CC3)C2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 9/20 0.46
FGFR1 P11362 4/20 0.43
EGFR P00533 3/20 0.43
PDGFRB P09619 3/20 0.43
PDGFRA P16234 3/20 0.43
FGFR2 P21802 3/20 0.43
FGFR3 P22607 3/20 0.43
KDR P35968 3/20 0.43
FYN P06241 2/20 0.43
MAPK1 P28482 2/20 0.43
EPHB3 P54753 2/20 0.43
PRKACA P17612 1/20 0.42
PRKACG P22612 1/20 0.42
PRKACB P22694 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
MAT2A P31153 8/20 0.39
NPBWR1 P48145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5770283 0.82 FGFR4 (0.66) FGFR4FGFR1EGFRPDGFRBPDGFRA
SCHEMBL16071567 0.82 FGFR4 (0.66) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL5767134 0.82 FGFR4 (0.59) FGFR4FGFR1EGFRPDGFRBPDGFRA
SCHEMBL16061133 0.81 FGFR4 (0.52) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL4686776 0.78 FGFR4 (0.47) FGFR4FGFR1EGFRPDGFRBPDGFRA
SCHEMBL16071565 0.76 FGFR4 (0.55) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL22532554 0.75 FGFR4 (0.53) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL29388619 0.75 FGFR4 (0.53) FGFR4FGFR1FGFR2FGFR3KDR
SCHEMBL5830862 0.74 FGFR4 (0.40) FGFR4FGFR1EGFRPDGFRBPDGFRA
SCHEMBL5830393 0.74 FGFR4 (0.40) FGFR4FGFR1EGFRPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115740-B2 Pyrimido compounds having antiproliferative activity HOFFMANN-LA ROCHE INC. (US) 2006-10-03 US disclosed
EP-1615928-A1 PYRIMIDO COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2006-01-18 EP disclosed
WO-2004089955-A1 PYRIMIDO COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2004-10-21 WO disclosed
US-20040204427-A1 Pyrimido compounds having antiproliferative activity CHEN YI (US) 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204427-A1 Pyrimido compounds having antiproliferative activity FGFR3, FGFR1, FGFR4 FGFR4 3/4885FGFR1 2/4885EGFR 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.